跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2007-005672-13-FR
EUCTR2007-005672-13-FR进行中（未招募）不适用

DOUBLE-BLIND STUDY, RANDOMISED, ACTIVE AND PLACEBO CONTROLLED TO ASSESS THE CLINICAL EFFICACY, SKIN TOLERABILITY AND PHARMACOLOGICAL ACTIVITY OF UR-1505 OINTMENT AT THREE DIFFERENT STRENGHTS IN PATIENTS WITH MILD TO MODERATE PLAQUE-TYPE PSORIASIS

PALAU PHARMA SA0 个研究点开始时间: 2007年11月13日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •- Sex: Male or female ·
  • •- Age: older than 18 and less than 75 years.
  • •- Phototype: I to IV according to the Fitzpatrick scale.
  • •- Patient with at least two eligible psoriatic plaques on equivalent topographic areas (arms, legs or trunk), each of a prefered size of 2% but in all cases smaller than 5% of body surface area.
  • •- For woman with child-bearing potential: use of a known, effective means of contraception (contraceptive pills, intra-uterine contraceptive device, tromp phallop ligation, implants, ring or condom) for at least 12 weeks prior to the study, during the study and one month after the end of the study.
  • •- Subject being psychologically able to understand information and to give his/her consent.
  • •- Subject having given freely and expressly his/her informed consent, cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by Group DERMSCAN can be expected.
  • •- Subject affiliated to a health social security system.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •- Subject with a loss of personal liberty, by administrative or judicial decision.
  • •- Minor or major with a legal guardian.
  • •- Subject in a social or sanitary establishment.
  • •- Subject in an emergency situation.
  • •- Volunteer having been paid more than 4500€ to take part in biomedical researches over the previous 12 months.·
  • •- Pregnant or nursing woman or planning to be pregnant during the study.
  • •- Subject likely to be non observant to the study according to the investigator interpretation.
  • •- Patient registered as being in exclusion period in the French Health Minister File of Patients.
  • •- Subject suffering from a serious or progressive disease(s) that the investigator judges may interfere with the study.
  • •- Subject with a congenital or established immunity defect.
  • •- Subject with potentially malign or pre cancerous lesions.
  • •- Subject having a cutaneous pathology on the test zones except psoriasis.
  • •- Subject with clinical signs of infection on the test zones.
  • •- Subject with know allergy or hypersensitivity to a constituent of the products (in particular to salicylic compounds or any of substances used as a vehicle), as well as allergy or hypersensitivity reactions to calcipotriol ointment 0.005%.
  • •- Subject with any other skin disease that makes implementation of the protocol or interpretation of the study results difficult at investigator criteria.
  • •- Subject with know hypercalcemia.
  • •- History of erythrodermic, pustular psoriasis or severe psoriasis requiring hospitalisation.
  • •- Unstable psoriasis or psoriasis other than plaque-type.
  • •- Use of any topical anti-psoriatic therapy in selected plaques within two weeks of the study entry and during the study.
  • •- Use of any systemic anti-psoriatic therapy (including phototherapy) within 8 weeks prior to the study entry and during the study.
  • •- Subject receiving topical or systemic medical treatment:
  • •* Acetylsalicylic acid, anti-inflammatory, antihistamines drugs, or antibiotics in the week preceding the D0 and during the study,
  • •*immuno-suppressors and/or corticoids in the month preceding the D0 and during the study (stabilized treatment with inhaled corticosteroids for asthma and/ or nasal topical steroids for rhinitis will be allowed),
  • •*Topical tar derivatives, psoralenes, phototherapy or vitamin D derivatives in the 3 weeks prior to randomization.
  • •*Systemic retinoids (ex: Roaccutane®) in the six months preceding the D0 and during the study,
  • •*Any other treatment stabilized likely to interfere the results since less than one month before the D0.
  • •- Subject who was exposed to an UV sun lamp or excessive exposure to the sun within the month prior to the study and during the study.
  • •- Subject using dermopharmaceutical or cosmetics products (including keratolytics, salicylic acid, lactic acid, urea) other than emollients on the tested area over the period of the study.
  • •- Subject who has a recent history (within previous 12 months) of drug addiction or alcohol abuse.
  • •- Active tobacco smoker (more than 10 cigarettes/day).
  • •Exclusions :
  • •- Patient who presents a Serious Adverse effect, imputable or not to one of the treatments.
  • •- Patient who does not collaborate in his/her treatment, under the conditions provided by the information consent.
  • •- Patient whose clinical condition requires the application of products on the studied lesions other than the tested and compensation treatments allowed by the protocol.

研究者

相似试验

已完成
不适用
DOUBLE BLIND STUDY PARALLEL RANDOMIZED AND ACTIVE COMPARATOR WHOSE PURPOSE IS TO EVALUATE THE SAFETY AND EFFICACY OF CELECOXIB IN SUSPENSION COMPARED WITH NAPROXEN IN SUSPENSION IN PATIENTS WITH YOUNG RHEUMATOID ARTHRITIS.
PER-049-02PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
进行中（未招募）
不适用
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensionEstudio aleatorizado, en doble ciego, controlado con producto activo y con placebo, de grupos paralelos y multicéntrico, para evaluar la eficacia y la seguridad de distintas dosis de CG5503 en formulación de liberación inmediata en el tratamiento del dolor agudo consecuencia de la cirugía de artroplastia total de cadera, seguido por una extensión abierta de carácter voluntariopainMedDRA version: 8.1Level: LLTClassification code 10033371Term: Pain
EUCTR2006-004513-18-ESJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100
进行中（未招募）
1 期
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensiopainMedDRA version: 8.1Level: LLTClassification code 10033371Term: Pain
EUCTR2006-004513-18-FRJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
进行中（未招募）
不适用
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extensio
EUCTR2006-004513-18-FIJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100
进行中（未招募）
不适用
Clinical trial to evaluate the clinical effect and safety of a triple combination of ibuprofen, magnesium and vitamin C in the treatment of acute pain in temporomandibular disorders (TMD).Temporomandibular joint dysfunction syndrome.
EUCTR2014-003790-41-ESSpherium Biomed